Thomas P. Monath
Infectious Diseases
CENTINEXT Therapeutics
Malaysia
Biography
Monath is a Chief Science Officer and Chief Operating Officer of BioProtection Systems/NewLink Genetics Corp (NASDAQ: NLNK), where he is engaged in development of Ebola vaccine and new vaccines against other infectious diseases. In his current position he is responsible for the development of the recombinant vesicular stomatitis-Ebola vaccine that has recently shown 100% efficacy in a Phase 3 trial in Guinea. The vaccine is exclusively licensed from NewLink to Merck. Monath’s expertise and experience cut across discovery research, process and analytical development, manufacturing, preclinical and clinical development, and regulatory affairs. Monath is also a Venture Partner at Kleiner Perkins Caufield & Byers and is a Director of Vaxinnate Inc., Sentinext plc, Rapid Micro Biosystems Inc, and Biologics Inc.
Research Interest
Research on all infectious Diseases
